Junyu Guo1, Qing Ji1, Mary E. McCarville1, Najat C. Daw2, Wilburn E. Reddick1
1Radiological Science, St Jude Children's Research Hospital, Memphis, TN, United States; 2Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, United States
A new osteosarcoma treatment protocol in our Institute includes a multiagent chemotherapy with an anti-angiogenic agent (bevacizumab). Serial DCE-MRI was performed at six different time points during neoadjuvant therapy, and a recently developed DCE-MRI data analysis method, the CPA method, was used to process the data and assess treatment response in the first eight patients. According to our preliminary results, it is feasible to assess the tumor treatment response to neoadjuvant therapy using the CPA method in DCE-MRI. Further investigation of this CPA method on a larger cohort of patients will be performed.